Therapeutic Areas

Therapeutic Areas

Cancer


 
Chipscreen Biosciences focuses on cancer therapies. Chidamide, the first original innovative drug discovered and developed by Chipscreen, was the first oral subtype-selective histone deacetylase (HDAC) inhibitor with a novel epigenetic modulating mechanism.
 
Over the last decade, a large body of scientific studies has found that epigenetics plays critical roles in the escape from host immune surveillance, differentiation of cancer stem cells associated with tumor recurrence, epithelial-to-mesenchymal transition (EMT) associated with tumor metastasis, and elimination of drug-resistant cells from heterogeneous tumors. Epigenetic drugs have thus become a key focus of drug research and development, and Chipscreen Biosciences has been working in this area for 20 years. In December 2014, Chidamide was approved by the CFDA for relapsed and refractory peripheral T-cell lymphoma (PTCL), its first approved indication. In November 2019, Chidamide was approved by the NMPA in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone receptor-positive, HER2-negative, recurrent or progressive locally advanced or metastatic breast cancer previously treated with endocrine therapy. This approval made Chidamide the first epigenetic drug approved for solid tumor therapy in the world, following groundbreaking evidence that Chidamide can effectively prevent tumor resistance in combination with other targeted drugs.

 

 


  
Metabolic Diseases


 
Metabolic diseases are the most common chronic conditions, these conditions typically cause health problems often related to damage to blood cerebral vessels and vital organs, such as heart, liver and kidney, etc. Short-term efficacy from the medicine and lack of efficacious treatment are the main contributors to the waste of medical resources and poor prognosis, thus there is a strong ongoing demand for treatment for metabolic disorders. 
 
Chiglitazar, our first product targeting metabolic diseases, is a configuration-restricted pan-PPAR agonist with a chemical structure completely different from thiazolidinedione compounds. As an innovative drug with a brand-new mechanism of action, no lessons could be drawn from the success of predecessors, and the lack of existing clinical studies on pan-PPAR agonists worldwide posed major difficulties to the research and development process. Chiglitazar eventually overcame these obstacles to achieve good results for both efficacy and safety, and is now the world’s first pan-PPAR agonist to complete phase III clinical trials. In September 2019, the new drug application (NDA) for Chiglitazar was accepted by the CDE. The unique pharmacodynamic molecular mechanism of Chiglitazar makes it an exciting prospect for both diabetes and its related complications, and clinical exploration for a range of conditions is currently underway.


The company is also in the early stages of developing candidate compounds targeting other metabolic diseases, such as hyperlipidemia, non-alcoholic steatohepatitis, and chronic kidney disease.

 

 

 

Autoimmune disorders


 
Autoimmune disorders is a general category for a large group of conditions featuring over 100 pathological types, including common diseases such as rheumatoid arthritis, psoriasis, and systemic lupus erythematosus, as well as various types of rare diseases. These conditions range in severity from minor impacts on quality of life to life-threatening. Due to the significant heterogeneity of pathological characteristics in different patients, clinical treatment tends to be ineffective, and in some cases no treatment exists. Therefore, new treatments are urgently demanded in the clinic.


Our first product in this field, CS12192, is currently undergoing clinical trials for different autoimmune conditions. CS12192 is a JAK3/JAK1/TBK1 selective kinase inhibitor with a novel mechanism, and differs markedly from other existing clinical drugs both in target selection and molecular mechanism. Unlike other JAK kinase inhibitors on the market, CS12192 not only effectively inhibits inflammation mediated by excessive activation of immune cells, but also suppresses TBK1 to reduce tissue invasion of immune cells, leading to better efficacy and safety. For these reasons, CS12192 is expected to provide a new and differentiated alternative treatment for autoimmune diseases.
 
Other potential therapeutic targets are also being investigated at the early stages of research and development in the hope of providing more innovative drugs for clinical treatment in this complex field.